-
Article
Open AccessHealth-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC...
-
Article
Open AccessPersonalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol
With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or rese...
-
Article
Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database
Skin phototype, latitude and sun exposure are classic risk factors for melanomas but are not relevant to acrolentiginous melanomas (ALM). ALM is not related to chronic sun exposure because the thick stratum co...
-
Article
Open AccessLong-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT015...
-
Article
Open AccessOutcome of early stage Merkel carcinoma treated by exclusive radiation: a study of 53 patients
Early stage Merkel cell carcinoma (MCC) is a rare and aggressive primary skin cancer. The standard of care for MCC is broad excision and adjuvant external beam radiation therapy (EBRT). However, for some patie...
-
Article
Open AccessAbrupt warming and salinification of intermediate waters interplays with decline of deep convection in the Northwestern Mediterranean Sea
The Mediterranean Sea is a hotspot for climate change, and recent studies have reported its intense warming and salinification. In this study, we use an outstanding dataset relying mostly on glider endurance l...
-
Article
Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database
Targeted therapies such as BRAF and MEK inhibitors and immunotherapies have been made available to treat melanoma.
-
Article
Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas
Adnexal carcinomas are rare and heterogeneous skin tumors, for which no standard treatments exist for locally advanced or metastatic tumors.
-
Article
Open AccessCorrection to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:
-
Chapter
18 Review of the Circulation and Characteristics of Intermediate Water Masses of the Mediterranean: Implications for Cold-Water Coral Habitats
This chapter describes the main features of the circulation and properties of the intermediate water masses of the Mediterranean. Interaction with other water masses is also briefly summarised. Both observatio...
-
Article
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study
Health-related quality of life (HRQoL) data are limited in patients with advanced basal cell carcinoma.
-
Article
Open AccessAntitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT0...
-
Article
Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors
The current classification of melanocytic tumors includes clinical, pathological, and molecular data. A subset of lesions remains difficult to classify according to these complex multilayer schemes. We report ...
-
Article
Open AccessGlucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors
Targeted therapies as BRAF and MEK inhibitor combination have been approved as first-line treatment for BRAF-mutant melanoma. However, disease progression occurs in most of the patients within few months of th...
-
Article
Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review
Understanding the molecular basis of basal cell carcinoma (BCC) has led to development of Hedgehog pathway inhibitors (HPIs) for patients with advanced forms of BCC (aBCC). A practical definition of aBCC as a ...
-
Article
Open AccessLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facili...
-
Article
Open AccessErratum to: Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
-
Article
Open AccessLow-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
The aim of this study is to analyze the results of exclusive interstitial brachytherapy (IBT) as a conservative approach in the treatment of penile cancer confined to the glans or the shaft with long-term foll...
-
Article
Open AccessMelanoma and immunotherapy bridge 2015
MELANOMA BRIDGE 2015
-
Article
Defining and recognising locally advanced basal cell carcinoma
Rarely, basal cell carcinomas (BCCs) have the potential to become extensively invasive and destructive, a phenomenon that has led to the term “locally advanced BCC” (laBCC). We identified and described the div...
